LitCovid-sentences  

PMC:7736111 / 149918-153192 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1036 0-19 Sentence denotes Future Perspectives
T1037 20-191 Sentence denotes Over the last several months, a large number of clinical and histological studies have illustrated the underlying pathophysiological changes and tissue damage in COVID-19.
T1038 192-326 Sentence denotes However, we are just beginning to understand the fundamental molecular and signaling pathways implicated in this disease pathogenesis.
T1039 327-579 Sentence denotes Close sequence similarity with SARS-CoV does help us understand some co-existing pathological features but owing to reasonable genomic and structural variations, and it is essential to decoding the molecular mechanisms specific to SARS-CoV-2 infection.
T1040 580-726 Sentence denotes Differences in S protein, ORF3b, ORF6 and ORF8 between SARS-CoV and SARS-CoV-2 are functionally relevant (Chan et al., 2020; Mantlo et al., 2020).
T1041 727-953 Sentence denotes Similarly, the differential immune responses generated by the two viruses needs to be delineated well to develop targeted therapies to modulate these specific molecular networks (Moreno-Eutimio et al., 2020; Yao et al., 2020).
T1042 954-1167 Sentence denotes Importantly, heterogeneous T cell response in COVID-19 patients has remained an enigma, with lymphocytopenia and activated T cell state in some patients versus an increased presence of exhausted T cells in others.
T1043 1168-1424 Sentence denotes Further, the increased activation status of these cells at the site of infection (lungs) in severe cases adds more complexity to the T cell immune response in COVID-19 patients and hence may pose difficulty in devising a universal therapeutic intervention.
T1044 1425-1583 Sentence denotes Similarly, the presence of reactive T cells in healthy individuals is another area that needs a comprehensive understanding, mainly while designing a vaccine.
T1045 1584-1920 Sentence denotes Keeping these challenges in mind and till the time an effective vaccine becomes available, existing immunomodulatory approaches like mesenchymal stem cell-based therapies (currently under clinical trials), anti-IL6 and anti-GMCSF drugs to counter cytokine storm, as well as antiviral drugs remain the standard therapeutic interventions.
T1046 1921-2065 Sentence denotes While the antiviral drug remdesivir has shown promise in some patients, severe side effects were also reported in others (Wang Y. et al., 2020).
T1047 2066-2256 Sentence denotes Considering the number of factors that affect the complexity of immune response during COVID-19, it is crucial to understand that a single type of intervention may not work for all patients.
T1048 2257-2345 Sentence denotes Thus, it appears that exploring a combination therapy may be more compelling at present.
T1049 2346-2454 Sentence denotes However, determination of the optimal combination, dose, and time of treatment needs thorough investigation.
T1050 2455-2535 Sentence denotes These targeted therapies become critical, considering the chance of reinfection.
T1051 2536-2751 Sentence denotes A recent study on ten healthy individuals throughout 35-years revealed short-lasting immunity against four common seasonal coronaviruses, with chances of reinfection in a year after infection (Edridge et al., 2020).
T1052 2752-2882 Sentence denotes It is plausible that SARS-CoV-2 may exhibit the same tendency of reinfection, which may be a growing concern for vaccine research.
T1053 2883-3010 Sentence denotes Thus, a more comprehensive understanding of the immunopathological changes and sustainability of protective immunity is needed.
T1054 3011-3149 Sentence denotes In this review, we highlight some of these immunological responses, which are central to the progression and outcome of COVID-19 patients.
T1055 3150-3274 Sentence denotes Ongoing research in this direction should lead to effective therapies sooner rather than later, alongside with the vaccines.